William K. Schmidt - 30 Jun 2021 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Reporting relationship: Chief Medical Officer
Issuer ticker: ENSC
Reported as of: 30 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2021, 18:08:04 UTC
Source filing: View source filing
Reporting owner signature: /s/ William Schmidt

Key filing fact

William K. Schmidt filed Form 4 for Ensysce Biosciences, Inc. (ENSC) on 02 Jul 2021.

Key facts

This page summarizes William K. Schmidt's Form 4 filing for Ensysce Biosciences, Inc. (ENSC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2021, 18:08.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENSC transaction Derivative

Stock Option

Award

Transaction value
Shares: +69,142
Change %
Price
Shares after: 69,142
Date: 30 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,142
Exercise price: $3.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.